Lou Jau-Shin, Dimitrova Diana M, Park Byung S, Johnson Sarah C, Eaton Ryan, Arnold Grace, Nutt John G
Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA.
Clin Neuropharmacol. 2009 Nov-Dec;32(6):305-10. doi: 10.1097/WNF.0b013e3181aa916a.
Fatigue is a major nonmotor symptom in Parkinson disease(PD). It is associated with reduced activity and lower quality of life.
To determine if modafinil improves subjective fatigue and physical fatigability in PD.
Nineteen PD patients who reported significant fatigue in the Multidimensional Fatigue Inventory (MFI) participated in this 8-week study. Subjects took their regular medications and were randomly assigned to the treatment group (9 subjects, modafinil 100-mg capsule BID) or placebo group (10 subjects). We used the MFI to measure subjective fatigue and used finger tapping and intermittent force generation to evaluate physical fatigability. Subjects also completed the Epworth Sleepiness Scale (ESS) and the Center of Epidemiological Study-Depression Scale.
There were no significant differences at baseline and at 1 month in finger tapping and ESS between the modafinil and placebo groups. At 2 months, the modafinil group had a higher tapping frequency (P<0.05), shorter dwell time (P<0.05), and less fatigability in finger tapping and tended to have lower ESS scores (P<0.12) than the placebo group. However, there was no difference between groups over time for any dimension of the MFI .
This small study demonstrated that although modafinil may be effective in reducing physical fatigability in PD, it did not improve fatigue symptoms.
疲劳是帕金森病（PD）的主要非运动症状。它与活动减少和生活质量降低有关。
确定莫达非尼是否能改善帕金森病患者的主观疲劳和身体易疲劳性。
19名在多维疲劳量表（MFI）中报告有明显疲劳的帕金森病患者参与了这项为期8周的研究。受试者继续服用常规药物，并被随机分为治疗组（9名受试者，服用100毫克莫达非尼胶囊，每日两次）或安慰剂组（10名受试者）。我们使用MFI来测量主观疲劳，并使用手指敲击和间歇性力量产生来评估身体易疲劳性。受试者还完成了爱泼华嗜睡量表（ESS）和流行病学研究中心抑郁量表。
在基线和1个月时，莫达非尼组和安慰剂组在手指敲击和ESS方面没有显著差异。在2个月时，莫达非尼组的敲击频率更高（P<0.05），停留时间更短（P<0.05），手指敲击时的易疲劳性更低，并且ESS得分往往比安慰剂组更低（P<0.12）。然而，在MFI的任何维度上，两组随时间的变化没有差异。
这项小型研究表明，虽然莫达非尼可能对降低帕金森病患者的身体易疲劳性有效，但它并不能改善疲劳症状。
